Junfeng Li

Dr. Junfeng Li

City of Hope National Medical Center
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Junfeng LiJunfeng Li
Junfeng Li
XZXiang Zhang
Xiang Zhang
ZZZhanbin Zhang
Zhanbin Zhang
PPPrashanth K. Padakanti
Prashanth K. Padakanti
HJHongjun Jin
Hongjun Jin
ZTZhude Tu
Zhude Tu

15 October 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Junfeng LiJunfeng Li
Junfeng Li
XZXiang Zhang
Xiang Zhang
HJHongjun Jin
Hongjun Jin
JFJinda Fan
Jinda Fan
HFHubert Flores
Hubert Flores
ZTZhude Tu
Zhude Tu

1 February 2015 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
HYHao Yang
Hao Yang
FMFrancis N. Murigi
Francis N. Murigi
ZWZhijian Wang
Zhijian Wang
Junfeng LiJunfeng Li
Junfeng Li
HJHongjun Jin
Hongjun Jin
ZTZhude Tu
Zhude Tu

1 May 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
JFJinda Fan
Jinda Fan
XZXiang Zhang
Xiang Zhang
Junfeng LiJunfeng Li
Junfeng Li
HJHongjun Jin
Hongjun Jin
PPPrashanth K. Padakanti
Prashanth K. Padakanti
ZTZhude Tu
Zhude Tu

12 May 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Junfeng LiJunfeng Li
Junfeng Li
HKHirotake Komatsu
Hirotake Komatsu
KPKofi Poku
Kofi Poku
TOTove Olafsen
Tove Olafsen
KHKelly Huang
Kelly Huang
FKFouad Kandeel
Fouad Kandeel
Umbilical cord mesenchymal stem cell-derived extracellular vesicles (UC-MSC-EVs) have become an emerging strategy for treating various autoimmune and metabolic disorders, particularly diabetes. Delivery of UC-MSC-EVs is essential to ensure optimal efficacy of UC-MSC-EVs. To develop safe and superior EVs-based delivery strategies, we explored nuclear techniques including positron emission tomography (PET) to evaluate the delivery of UC-MSC-EVs in vivo. In this study, human UC-MSC-EVs were first successfully tagged with I-124 to permit PET determination. Intravenous (I.V.) and intra-arterial (I.A.) administration routes of [124I]I-UC-MSC-EVs were compared and evaluated by in vivo PET-CT imaging and ex vivo biodistribution in a non-diabetic Lewis (LEW) rat model. For I.A. administration, [124I]I-UC-MSC-EVs were directly infused into the pancreatic parenchyma via the celiac artery. PET imaging revealed that the predominant uptake occurred in the liver for both injection routes, and further imaging characterized clearance patterns of [124I]I-UC-MSC-EVs. For biodistribution, the uptake (%ID/gram) in the spleen was significantly higher for I.V. administration compared to I.A. administration (1.95 ± 0.03 and 0.43 ± 0.07, respectively). Importantly, the pancreas displayed similar uptake levels between the two modalities (0.20 ± 0.06 for I.V. and 0.24 ± 0.03 for I.A.). Therefore, our initial data revealed that both routes had similar delivery efficiency for [124I]I-UC-MSC-EVs except in the spleen and liver, considering that higher spleen uptake could enhance immunomodulatory application of UC-MSC-EVs. These findings could guide the development of safe and efficacious delivery strategies for UC-MSC-EVs in diabetes therapies, in which a minimally invasive I.V. approach would serve as a better delivery strategy. Further confirmation studies are ongoing.

17 December 2012 in MedChemComm
Verified
Journal Article
Closed access
PDF file
Junfeng LiJunfeng Li
Junfeng Li
HJHongjun Jin
Hongjun Jin
HZHaiying Zhou
Haiying Zhou
JRJustin Rothfuss
Justin Rothfuss
ZTZhude Tu
Zhude Tu
Twenty eight new analogues were synthesized by optimizing the structure of MP-10 and their in vitro binding affinities towards PDE10A, PDE3A/B, and PDE4A/B were determined. Among these new analogues, 10a, 10b, 10d, 11a, 11b and 11d are very potent towards PDE10A and have IC50 values of 0.40 ± 0.02, 0.28 ± 0.06, 1.82 ± 0.25, 0.24 ± 0.05, 0.36 ± 0.03 and 1.78 ± 0.03 nM respectively; these six compounds displayed high selectivity for PDE10A versus PDE3A/3B/4A/4B. The promising compounds will be further validated in vivo to identify PDE10A imaging tracers.